(redirected from Hyperacute rejection)
Also found in: Dictionary, Thesaurus, Medical, Legal, Encyclopedia.


Refusal by a bank to grant credit, usually because of the applicants financial history, or refusal to accept a security presented to complete a trade, usually because of a lack of proper endorsements or violation of rules of a firm.


1. A bank's refusal to grant a line of credit. This often applies to the refusal to grant a mortgage loan to an uncreditworthy person or a business loan to someone without a proper business plan.

2. An investor's refusal to accept a security presented to him/her/it. Reasons for this include suspicion of fraud or improperly filled-out forms.

3. Refusal to provide insurance coverage because the insurance company believes that the claim describes a service or situation that the policy does not cover.


The refusal to accept a security that has been delivered by a customer or broker. A questionable certificate or an improper endorsement are reasons for rejection.
References in periodicals archive ?
Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction.
Investigators placing pig organs in other animal species have stemmed endothelial cell activation and the resulting hyperacute rejection by depleting a prospective recipient's store of alpha-gal antibodies before the xenotransplant.
The major strategies used to reduce hyperacute hyperacute rejection such as depletion of anti-Gal antibodies and genetic engineering of swine to express human complement regulatory proteins to decrease complement deposition, might impact host defenses against viral infection (Meije et al.
Even postulating a greatly diminished or eliminated risk of hyperacute rejection, immunologic barriers to xenotransplantation will probably be more significant than those of allotransplantation.
4 /PRNewswire/ -- La Jolla Pharmaceutical Company (Nasdaq: LJPC) today announced that it has completed the laboratory testing and development of a new, five-fold-more potent Toleragen(R) candidate designed to arrest the production of antibodies responsible for hyperacute rejection in xenotransplantation, the use of animal organs for human transplantation.
assistant professor of surgery, whose gene sequencing work contributed a key understanding that allowed PPL to move forward and achieve two more significant milestones involving the creation of cloned pigs lacking the gene associated with hyperacute rejection, thus removing a major immune barrier between pig and human and making transplants from animals to humans more feasible.
The report, published February 8Th by the Department of Health, notes that genetic modification of source animals to knock-out the genes responsible for hyperacute rejection and to add new genes necessary to control later rejection is promising but remains in the very early stages.
vice president of research and development at Nextran, who today is presenting at IBC's Xenotransplantation Conference in San Diego, stated "Through this collaboration with Cytel, we expect to minimize the most significant immunological barrier to transplantation of pig organs -- hyperacute rejection.
This pig sugar (alpha 1,3 galactose) triggers an immune response in the human patient, leading to hyperacute rejection of the transplanted organ or cell within minutes.